Bidisomide is a synthetic, orally active, small-molecule, non-nucleoside inhibitor of HIV-1 reverse transcriptase. It was initially developed in the 1990s, but it was discontinued in clinical trials due to concerns about its safety profile. It is a potent and selective inhibitor of HIV-1 reverse transcriptase, with IC50 values in the nanomolar range. Its mechanism of action involves binding to the non-nucleoside binding site of HIV-1 reverse transcriptase, which is located in a hydrophobic pocket near the active site. This binding event disrupts the enzyme's catalytic activity and prevents the conversion of viral RNA into viral DNA, thereby inhibiting viral replication. Bidisomide was studied for its potential to treat HIV infection. It was investigated for its ability to inhibit HIV-1 replication in vitro and in vivo. However, clinical trials were terminated due to concerns about its potential for hepatotoxicity. '
bidisomide: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 59798 |
| CHEMBL ID | 305745 |
| CHEBI ID | 135658 |
| SCHEMBL ID | 120852 |
| MeSH ID | M0171749 |
| Synonym |
|---|
| bidisomide |
| sc-40230 , |
| D03113 |
| bidisomide (usan/inn) |
| 116078-65-0 |
| bidisomida [inn-spanish] |
| bidisomidum [inn-latin] |
| brn 6536016 |
| bidisomide (+-)- |
| bidisomide [usan:inn] |
| 1-piperidinebutanamide, alpha-(2-(acetyl(1-methylethyl)amino)ethyl)-alpha-(2-chlorophenyl)-, (+-)- |
| (+-)-alpha-(o-chlorophenyl)-alpha-(2-(n-isopropylacetamido)ethyl)-1-piperidinebutyramide |
| sc 40230 |
| CHEBI:135658 |
| CHEMBL305745 |
| 2-[2-[acetyl(propan-2-yl)amino]ethyl]-2-(2-chlorophenyl)-4-piperidin-1-ylbutanamide |
| bidisomida |
| unii-2x3z153a4o |
| bidisomidum |
| 2x3z153a4o , |
| (+/-)-.alpha.-(o-chlorophenyl)-.alpha.-(2-(n-isopropylacetamido)ethyl)-1-piperidinebutyramide |
| 1-piperidinebutanamide, .alpha.-(2-(acetyl(1-methylethyl)amino)ethyl)-.alpha.-(2-chlorophenyl)-, (+/-)- |
| bidisomide [usan] |
| bidisomide [mi] |
| bidisomide [inn] |
| SCHEMBL120852 |
| alpha-[2-[acetyl(1-methylethyl)amino]ethyl]-alpha-(2-chlorophenyl)-1-piperidinebutanamide |
| alpha-[2-[acetyl (1-methylethyl)amino]ethyl]-alpha-(2-chlorophenyl)-1-piperidinebutanamide |
| GTEPPJFJSNSNIH-UHFFFAOYSA-N |
| sc40230 |
| 103810-45-3 |
| HY-U00232 |
| CS-7390 |
| Q27255735 |
| MS-27002 |
| 2-(2-chlorophenyl)-4-(n-isopropylacetamido)-2-(2-(piperidin-1-yl)ethyl)butanamide |
| DTXSID60869599 |
| 1-piperidinebutanamide,a-[2-[acetyl(1-methylethyl)amino]ethyl]-a-(2-chlorophenyl)- |
| AKOS040737670 |
Bidisomide is a Class Ia/Ib antiarrhythmic agent with activity against ventricular and supraventricular arrhythmias.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Bidisomide is a Class Ia/Ib antiarrhythmic agent with activity against ventricular and supraventricular arrhythmias. " | ( The effect of bidisomide (SC-40230), a new class Ia/Ib antiarrhythmic agent, on defibrillation energy requirements in dogs with healed myocardial infarctions. Gardiner, P; Garthwaite, SM; Hackett, AM, 1993) | 2.09 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " In man, the di-cationic disobutamide was slowly eliminated with a mean terminal phase half-life of 54 +/- 18 h, a value > 7 times longer than disopyramide." | ( Importance of pharmacokinetic and physicochemical data in the discovery and development of novel anti-arrhythmic drugs. Cook, CS; Karim, A; McDonald, SJ, 1993) | 0.29 |
| " This semicompartmental solution does not require the specification of a compartmental model for the pharmacokinetic response and may offer an advantage when model misspecification is present in using standard compartmental models." | ( A semicompartmental modeling approach for pharmacodynamic data assessment. Karim, A; Kowalski, KG, 1995) | 0.29 |
Bidisomide AUC was decreased since it was well absorbed in the upper but not lower small intestine. The absolute bioavailability of bidisomide was 45-62% which is lower than that of disopyramide (60-90%)
| Excerpt | Reference | Relevance |
|---|---|---|
| " The absolute bioavailability of bidisomide was 45-62% which is lower than that of disopyramide (60-90%)." | ( Importance of pharmacokinetic and physicochemical data in the discovery and development of novel anti-arrhythmic drugs. Cook, CS; Karim, A; McDonald, SJ, 1993) | 0.57 |
| " Bidisomide AUC was decreased since it was well absorbed in the upper but not lower small intestine." | ( Reduced systemic availability of an antiarrhythmic drug, bidisomide, with meal co-administration: relationship with region-dependent intestinal absorption. Cook, C; Fleisher, D; Kararli, T; Karim, A; Kirchhoff, C; Pao, LH; Truelove, J; Zhou, SY, 1998) | 1.46 |
| Class | Description |
|---|---|
| acetamides | Compounds with the general formula RNHC(=O)CH3. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID142361 | Ratio of Muscarinic acetylcholine receptor affinity (IC50) of test compound to that of disopyramide; 1/24 | 1988 | Journal of medicinal chemistry, Nov, Volume: 31, Issue:11 | Synthesis and structure-activity relationships of a new series of antiarrhythmic agents: monobasic derivatives of disobutamide. |
| AID59391 | Mean effective dose required to suppress ventricular ectopic rate in dog greater than or equal to 25% for a minimum duration of 10 min | 1988 | Journal of medicinal chemistry, Nov, Volume: 31, Issue:11 | Synthesis and structure-activity relationships of a new series of antiarrhythmic agents: monobasic derivatives of disobutamide. |
| AID419499 | Volume of distribution at steady state in human at 1 mg/kg, iv administered 20 mins infusion | 2009 | Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14 | In silico prediction of volume of distribution in human using linear and nonlinear models on a 669 compound data set. |
| AID60639 | Myocardial depression determined by monitoring the maximum rate of rise of left ventricular pressure in dog at 9 mg/kg dose | 1988 | Journal of medicinal chemistry, Nov, Volume: 31, Issue:11 | Synthesis and structure-activity relationships of a new series of antiarrhythmic agents: monobasic derivatives of disobutamide. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (13.04) | 18.7374 |
| 1990's | 17 (73.91) | 18.2507 |
| 2000's | 3 (13.04) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (115.04) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 5 (21.74%) | 5.53% |
| Reviews | 1 (4.35%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 17 (73.91%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||